چاپ صفحه |  صفحه نخست سامانه |  چکیده مقاله |  نویسندگان |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| Abstract: Immunotherapy is a new pillar of cancer therapy that provides novel opportunities to treat solid tumors. In this context, the development of new drugs targeting immune checkpoints is considered a promising approach in colorectal cancer (CRC) treatment because it can be induce specific and durable anti-cancer effects. Despite many advances in the immunotherapy of CRC, there are still limitations and obstacles to successful treatment. The immunosuppressive function of the tumor microenvironment (TME) is one of the causes of poor response to treatment in CRC patients. For this reason, checkpoint-blocking antibodies have shown promising outcomes in CRC patients by blocking inhibitory immune checkpoints and enhancing immune responses against tumors. This review summarizes recent advances in immune checkpoint inhibitors (ICIs), such as CTLA-4,PD-1,PD-L1,LAG-3,andTIM-3inCRC,anditdiscussesvarioustherapeuticstrategieswith ICIs,includingthedoubleblockadeofICIs,combinationtherapyofICIswithotherimmunotherapies, and conventional treatments. This review also delineates a new hopeful path in the combination of anti-PD-1/anti-PD-L1 with other ICIs such as anti-CTLA-4, anti-LAG-3, and anti-TIM-3 for CRC treatment |
| نویسنده | نفر چندم مقاله |
|---|---|
| زهرا اسدزاده | دوم |
| نیما همت | سوم |
| امیر باغبانزاده | چهارم |
| فرید قربانی نژاد | ششم |
| بهزاد برادران | یازدهم |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| 551-Immune Checkpoint Inhibitors in Colorectal Cancer.pdf | 1400/07/03 | 1895508 | دانلود |
